Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 2.8 uM | Cytotoxic activity against Murine Lymphocytic Leukemia P388 Concentration of agent required to reduce cell viability by 50% | ChEMBL. | 10377219 |
IC50 (functional) | = 2.8 uM | Cytotoxic activity against Murine Lymphocytic Leukemia P388 Concentration of agent required to reduce cell viability by 50% | ChEMBL. | 10377219 |
IC50 (functional) | = 3.4 uM | Cytotoxic activity against solid tumor, B16 (murine melanoma) Concentration of agent required to reduce cell viability by 50% | ChEMBL. | 10377219 |
IC50 (functional) | = 3.4 uM | Cytotoxic activity against solid tumor, B16 (murine melanoma) Concentration of agent required to reduce cell viability by 50% | ChEMBL. | 10377219 |
IC50 (functional) | = 5.6 uM | Cytotoxic activity against solid tumor, CHO (Chinese hamster ovaric carcinoma)Concentration of agent required to reduce cell viability by 50% | ChEMBL. | 10377219 |
IC50 (functional) | = 8.2 uM | Cytotoxic activity against Human promyelocytic Leukemia HL-60 Concentration of agent required to reduce cell viability by 50% | ChEMBL. | 10377219 |
IC50 (functional) | = 8.2 uM | Cytotoxic activity against Human promyelocytic Leukemia HL-60 Concentration of agent required to reduce cell viability by 50% | ChEMBL. | 10377219 |
IC50 (functional) | = 10 uM | Cytotoxic activity against solid tumor LLC(Lewis lung carcinoma), concentration of agent required to reduce cell viability by 50% | ChEMBL. | 10377219 |
IC50 (functional) | = 11 uM | Cytotoxic activity of the compound against solid tumor, LoVo, (human colon adenocarcinoma)Concentration of agent required to reduce cell viability by 50% | ChEMBL. | 10377219 |
IC50 (functional) | = 11 uM | Cytotoxic activity of the compound against solid tumor, LoVo, (human colon adenocarcinoma)Concentration of agent required to reduce cell viability by 50% | ChEMBL. | 10377219 |
IC90 (functional) | = 5.9 uM | Cytotoxic activity Murine Lymphocytic Leukemia P388 Concentration of agent required to reduce cell viability by 90% | ChEMBL. | 10377219 |
IC90 (functional) | = 5.9 uM | Cytotoxic activity Murine Lymphocytic Leukemia P388 Concentration of agent required to reduce cell viability by 90% | ChEMBL. | 10377219 |
IC90 (functional) | = 11 uM | Cytotoxic activity against solid tumor, B16 (murine melanoma) Concentration of agent required to reduce cell viability by 90% | ChEMBL. | 10377219 |
IC90 (functional) | = 11 uM | Cytotoxic activity against solid tumor, B16 (murine melanoma) Concentration of agent required to reduce cell viability by 90% | ChEMBL. | 10377219 |
IC90 (functional) | = 20 uM | Cytotoxic activity of the compound against solid tumor, CHO (Chinese hamster ovaric carcinoma)Concentration of agent required to reduce cell viability by 90% | ChEMBL. | 10377219 |
IC90 (functional) | = 27 uM | Cytotoxic activity against Human promyelocytic Leukemia HL-60 Concentration of agent required to reduce cell viability by 90% | ChEMBL. | 10377219 |
IC90 (functional) | = 27 uM | Cytotoxic activity against Human promyelocytic Leukemia HL-60 Concentration of agent required to reduce cell viability by 90% | ChEMBL. | 10377219 |
IC90 (functional) | = 32 uM | Cytotoxic activity against solid tumor LLC(Lewis lung carcinoma), concentration of agent required to reduce cell viability by 90% | ChEMBL. | 10377219 |
IC90 (functional) | = 36 uM | Cytotoxic activity of the compound against solid tumor, LoVo, (human colon adenocarcinoma)Concentration of agent required to reduce cell viability by 90% | ChEMBL. | 10377219 |
IC90 (functional) | = 36 uM | Cytotoxic activity of the compound against solid tumor, LoVo, (human colon adenocarcinoma)Concentration of agent required to reduce cell viability by 90% | ChEMBL. | 10377219 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | 10377219 | |
Mus musculus | ChEMBL23 | 10377219 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.